Following a full submission
AWMSG advice |
||
| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED OCTOBER 2009. Refer to TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | topotecan hydrochloride (Hycamtin®) | |
| Formulation | powder for concentrate for solution for infusion | |
| Reference number | 316 | |
| Indication | In combination with cisplatin for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease |
|
| Company | GlaxoSmithKline | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Full | |
| Status | Superseded | |
| Advice number | 0208 | |
| NMG meeting date | 16/01/2008 | |
| AWMSG meeting date | 14/02/2008 | |
| Ratification by Welsh Government | 06/03/2008 | |
| Date of issue | 20/03/2008 | |
| NICE guidance | TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer |
|